RegeneRx links with G-treeBNT to develop RGN-259 in the USA

29 January 2015

US biotech firm RegeneRx Biopharmaceuticals (OTC Bulletin Board: RGRX) has entered into agreements with South Korea-based G-treeBNT (KOSDAQ: 115450) to develop RGN-259 for dry eye syndrome and neurotrophic keratitis (an orphan indication) in the USA.

Under the terms of a joint venture (JV) agreement between the parties, G-treeBNT will be responsible for conducting and funding all clinical trials and product development through approval of a New Drug Application. RegeneRx granted the JV an exclusive, royalty-bearing license to market and sell RGN-259 in the USA. RegeneRx also contributed all of its non-clinical and clinical data generated to date.

G-treeBNT to be majority stakeholder

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK